JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential.
作者信息
Campiotti Leonardo, Elli Lorenzo, Suter Matteo B, Guasti Luigina, Pallotti Francesco
机构信息
Department of Medicine and Surgery, Università degli Studi dell'Insubria, Varese, Italy.
SSD Laboratorio Analisi - SMEL Specializzato in Citogenetica e Genetica Medica, ASST Sette laghi, Varese, Italy.
出版信息
Clin Chem Lab Med. 2019 Dec 18;58(1):e24-e26. doi: 10.1515/cclm-2019-0158.
PMID:31339852
Abstract
摘要
相似文献
1
JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential.
Clin Chem Lab Med. 2019 Dec 18;58(1):e24-e26. doi: 10.1515/cclm-2019-0158.
2
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.
Ann Hematol. 2011 Mar;90(3):365-6. doi: 10.1007/s00277-010-1009-y. Epub 2010 Jun 16.
3
Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm.
Int J Lab Hematol. 2015 Dec;37(6):e150-2. doi: 10.1111/ijlh.12398. Epub 2015 Jun 18.
4
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
Int J Hematol. 2008 Sep;88(2):243-245. doi: 10.1007/s12185-008-0131-2. Epub 2008 Jul 16.
5
Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm.
Clin Chem Lab Med. 2021 May 10;59(10):e392-e394. doi: 10.1515/cclm-2020-1884. Print 2021 Sep 27.
6
The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
Lab Hematol. 2012 Dec;18(4):20-1. doi: 10.1532/LH96.12009.
7
Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.
8
JAK2 mutation and atypical chronic myeloid leukemia.
Leuk Res. 2009 Sep;33(9):e166-7. doi: 10.1016/j.leukres.2009.03.045. Epub 2009 May 7.
9
Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Am J Case Rep. 2020 Oct 6;21:e925151. doi: 10.12659/AJCR.925151.
10
Insights into JAK2-V617F mutation in CML.
Lancet Oncol. 2007 Oct;8(10):863-4. doi: 10.1016/S1470-2045(07)70294-2.
Zotero 插件